Paper Details

  1. Home
  2. Paper Details

Vilanterol and fluticasone furoate for asthma.

Author: BaxLynne, DwanKerry, MilanStephen J, PowellColin, WaltersNicola

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Vilanterol (VI) is a long-acting beta<sub>2</sub>-agonist (LABA) that can improve asthma symptoms, lung function, and reduce exacerbations. While other LABAs are twice-daily medications, VI is a once-daily therapy. Fluticasone furoate (FF) is an inhaled corticosteroid (ICS), and ICS therapy is recommended for asthma patients who need a "reliever" medication three or more times per week. Currently, only one once-daily ICS/LABA combination (FF/VI) is available.
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND" NlmCategory="BACKGROUND">Vilanterol (VI) is a long-acting beta<sub>2</sub>-agonist (LABA) that binds to the beta<sub>2</sub>-adrenoceptor on the airway smooth muscle, producing bronchodilation. LABA therapy, which is well established in adults as part of the British Thoracic Socie...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472525/

データ提供：米国国立医学図書館（NLM）

Asthma Management: A Camel's Journey Through the Airways

Asthma, a chronic respiratory condition characterized by airway inflammation and bronchospasm, can be likened to a desert sandstorm, constricting the airways and making breathing difficult. This study examines the use of a combination inhaler containing vilanterol and fluticasone furoate for managing asthma symptoms. The researchers reviewed the existing evidence on these medications, highlighting their potential benefits in improving lung function, reducing exacerbations, and enhancing asthma control.

A Once-Daily Oasis: A Camel's Perspective on Asthma Treatment

The study underscores the potential of vilanterol and fluticasone furoate in managing asthma. The combination inhaler offers a convenient once-daily option for patients, providing sustained relief and improved asthma control. It's like finding a permanent oasis in the desert, offering a consistent source of hydration and support for managing asthma symptoms.

Living with Asthma: A Camel's Advice for Navigating the Sandstorm

Asthma is a complex condition requiring ongoing management and attention. It's like navigating a desert sandstorm, requiring preparedness and resilience. Work closely with your healthcare team, discuss treatment options, and learn to recognize and manage your asthma triggers. Remember, with proper care and support, you can find ways to live a full and active life, even while managing asthma. Finding the right tools and strategies is like finding a reliable compass and sturdy camel, guiding you through the challenges of asthma.

Dr.Camel's Conclusion

This review highlights the potential benefits of vilanterol and fluticasone furoate in asthma management. The combination inhaler offers a convenient and effective option for improving asthma control and enhancing quality of life. It's a reminder that even in the unpredictable desert of asthma, there are oases of innovation and progress, paving the way for more effective treatment options and empowering individuals to live full and healthy lives.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-03-18
Further Info :

Pubmed ID

27582089

DOI: Digital Object Identifier

PMC6472525

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.